What is Human Cell?
Human Cell Corporation is a specialized biotechnology firm focused on the large-scale manufacturing of human cells. The company distinguishes itself by providing long-acting and xeno-free cytokines derived from HEK293 cells, a critical component for advancing cell therapy and regenerative medicine. Furthermore, Human Cell offers manufacturing services for low-endotoxin recombinant proteins, essential for preclinical research and animal model studies in the pharmaceutical industry. Their commitment to innovation supports clients engaged in cutting-edge biotechnology and pharmaceutical research, aiming to accelerate scientific discovery and therapeutic development.
How much funding has Human Cell raised?
Human Cell has raised a total of $30K across 1 funding round:
Debt
$30K
Debt (2021): $30K with participation from PPP
What's next for Human Cell?
With the recent substantial expansion capital, Human Cell is poised for significant growth. The company's strategic focus on scalable, high-quality cell manufacturing solutions, coupled with its expertise in recombinant protein production, positions it to capitalize on the burgeoning demand for advanced biotherapeutics. This investment will likely be directed towards enhancing production capabilities, expanding research and development initiatives, and broadening its market reach within the global pharmaceutical and biotechnology landscape. The company's trajectory suggests a continued emphasis on innovation and operational excellence to meet the evolving needs of its clientele.
See full Human Cell company page
